In the Losartan Intervention For Endpoint reduction (LIFE) study left ventricular (LV) hypertrophy was associated with increased urine albumin/creatinine ratio (UACR) at baseline. To evaluate whether this association was due only to parallel blood pressure (BP)-induced changes we re-examined the patients after 1 year of antihypertensive treatment to investigate whether changes in LV hypertrophy and UACR were related independently of changes in BP. In 7142 hypertensive patients included in the LIFE study, we measured UACR, LV hypertrophy by electrocardiography, plasma glucose and BP after 2 weeks of placebo treatment and again after 1 year of antihypertensive treatment with either an atenolol or a losartan based regime. At baseline and still after 1 year of treatment logUACR (R = 0.28, P Ͻ 0.001) was still correlated to LV hypertrophy (␤ = 0.05) assessed by ECG independently of systolic BP (␤ = 0.16), plasma glucose (␤ = 0.19) and age (␤
Introduction
Microalbuminuria and left ventricular (LV) hypertrophy are both associated with essential hypertension [1] [2] [3] and have both been shown to be strong cardiovascular risk factors. 3, 4 In mild, uncomplicated hypertension the main determinant of urine albumin excretion is thought to be increased haemodynamic load, 2, 5, 6 whereas increased glomerular vascular permeability as part of a generalised vascular dysfunction 7 is thought to be increasingly important for elevation of urine albumin excretion in moderate to severe hypertension, especially if associated with metabolic abnormalities. 8, 9 Although elevated urine albumin excretion has been associated with many known cardiovascular risk factors like blood pressure (BP), 2 smoking, 10 serum homocysteine, 11 racial differences, 12 LV hypertrophy, 6 plasma glucose and serum insulin, 9 elevated urine albumin excretion has in some studies been demonstrated to be an independent predictor of cardiovascular disease and increased all-cause mortality in non-diabetic subjects as well as in patients with hypertension. 4, 13, 14 In hypertensive patients with LV hypertrophy on electrocardiography (ECG) we recently found that elevated urine albumin excretion assessed as increased urine albumin/creatinine ratio (UACR) and LV mass assessed by ECG were related to high BP suggesting parallel cardiac and glomerular vascular damage. 15 However, LV mass and UACR were at the same time related to each other independently of systolic BP indicating a more direct relationship between cardiac and glomerular vascular damage.
In an attempt to investigate, whether these parallel changes in UACR and indices of LV hypertrophy in our patients with longstanding hypertension and LV hypertrophy on ECG were more than BP dependent, we re-examined the patients after 1 year of antihypertensive treatment with significant BP reductions. We expected a reduction in UACR and a regression in LV mass parallel to the reduction in BP. If the association between changes in UACR and changes in LV mass remained significant independently of changes in systolic BP a more direct relationship would be likely.
Methods

Subjects
We examined a subgroup of 7142 patients included in the Losartan Intervention For Endpoint reduction (LIFE) study 16 with stage I-III hypertension and LV hypertrophy assessed by a screening ECG (sexadjusted Cornell voltage duration criteria or Sokolow-Lyon voltage criteria) from whom we had obtained urine samples at baseline and after 1 year of antihypertensive treatment. Patients were enrolled in Denmark, Finland, Iceland, Norway, Sweden, United Kingdom, and the United States. The patients had given informed consent and the Committees of Ethical Science in participating countries had accepted the study. The baseline and one year characteristics of the patients are listed in Table 1 . 
Blood pressure
According to the protocol of the LIFE study sitting BP was measured at the time of randomisation and after 1 year of antihypertensive treatment using a manual mercury sphygmanometer.
Electrocardiography
An ECG with carefully placed electrodes was performed at the time of randomisation and after 1 year of antihypertensive treatment. All ECGs were interpreted at the Core Laboratory at Sahlgrenska University Hospital/Ö stra in Gö teborg, Sweden by experienced investigators blinded to clinical information. The degree of LV hypertrophy was assessed by the product of QRS duration times the Cornell voltage combination (R aVL +S v3 +6 mm in women) or Sokolow-Lyon voltage summation (S v1 + R v5/6 ). 17 QRS duration was measured to the nearest 4 ms, and the R and S waves amplitydes were measured to the nearest 0.05 mV.
Urine albumin excretion
Urine albumin concentration was determined by standard methods 18, 19 by using a turbidimetric method (Hitachi  717  analyser,  Boeringer  Mannheim) 20,21 on a single urine specimen taken on the morning of electrocardiography. Both serum and urine creatinine was analysed using the Jaffé reaction without deproteinizing and then quantified by a photometric method (Hitachi 717 analyser, Boeringer Mannheim). The urine-albumin concentration, expressed as a ratio to the urinary creatinine concentration, was used as a measure of glomerular vascular permeability to allow for urine dilution. We defined microalbuminuria as UACR у3.5 mg/mmol and macroalbuminuria as UACR у35.0 mg/mmol. 22 Plasma glucose concentrations were measured using a Beckmann glucose analyser (Beckman Instruments Inc, Fullerton, CA, USA) and a glucose oxidase method.
Statistics
Statistical analyses were done using SPSS 9.0 statistical software (SPSS, Chicago, IL, USA). UACR was logarithm transformed in order to satisfy normality. Parametric statistics were used and the values were expressed as mean ± standard deviations. When comparing groups unpaired t-test was used, and when comparing baseline and 1-year data paired t-test was used. Simple linear regression analyses and stepwise, backward multiple linear regression analyses were performed. P-values of less than 0.05 were considered statistically significant.
Results
After 1 year of treatment the systolic BP was reduced by 24 ± 17 mm Hg and diastolic BP by 13 ± 9 mm Hg. At baseline UACR was significantly higher in African Americans, Hispanics and Asians as compared to Caucasians (13.7 mg/mmol vs 7.2 mg/ mmol, P Ͻ 0.001) and the reduction in UACR was also more pronounced in African Americans, Hispanics and Asians as compared to Caucasians (change in logUACR: 0.53 vs 0.31, P Ͻ 0.001). Plasma glucose concentrations increased across 1 year of treatment less in Caucasians as compared with African Americans, Hispanics and Asians (0.22 mmol/l vs 0.53 mmol/l, P Ͻ 0.01), and systolic BP was equally reduced in the two groups (24 mm Hg vs 25 mm Hg, NS).
At baseline and after 1 year of treatment logUACR was correlated to LV hypertrophy, systolic BP, plasma glucose, smoking and age, and the change in logUACR during treatment was also correlated to the changes in LV hypertrophy, in systolic BP and in plasma glucose (Table 2 ). In multiple regression analyses these correlations were independent of each other (Table 3) . At baseline and after 1 year of treatment LV hypertrophy as well as change in LV hypertrophy assessed by Sokolow-Lyon voltage summation and by sex-adjusted Cornell voltage-duration product were related to logUACR independently of systolic BP (Table 4) .
Discussion
UACR as well as indices of LV hypertrophy were related to systolic BP suggesting parallel cardiac and glomerular vascular damage as assessed by UACR in hypertensive patients with LV hypertrophy assessed by ECG. Even though UACR and LV mass assessed Definition of smoking variable: 0 = None-smoker; 1 = Ex-smoker; 2 = 1-5 cigarettes a day; 3 = 6-10 cigarettes a day; 4 = 11-20 cigarettes a day; 5 = more than 20 cigarettes a day. by ECG were related to systolic BP, the association between them existed independently of systolic BP at baseline and after 1 year of antihypertensive treatment, as well as independently of changes in systolic BP during treatment. These BP independent relationship support previous findings 23, 24 and suggest either a BP independent pathogenetic or genetic relationship between cardiac and glomerular vascular damage in hypertension.
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As elevated urine albumin excretion has been associated with an increased transcapillary albumin escape reflecting systemic transvascular leakiness and coronary artery disease 25 increased UACR has been hypothesised to be an indicator of generalised Journal of Human Hypertension vascular damage.
7 This is supported by Pontremoli et al, 26, 27 Mykkanen et al, 28 Bigazzi et al 29 and our own data, 30 who all found an association between high intima-media thickness (IMT) in the common carotid arteries and elevated urine albumin excretion. Therefore, we suggest that the BP independent relationship between increased UACR and LV hypertrophy on ECG is due to systemic vascular changes associated with increased UACR. Vascular changes have in other studies been demonstrated to promote LV hypertrophy independent of BP. 31, 32 Another possible explanation for the BP independent relationship between UACR and indices of LV hypertrophy might be that the cardiovascular system in some patients genetically is more prone to BP-induced cardiovascular changes involving the LV as well as the glomerular capillaries. These patients might also be more prone to regression of cardiovascular changes following BP reduction during antihypertensive treatment. The association between elevated urine albumin excretion and cardiovascular hypertrophy in essential hypertension demonstrated by us 15 and others 23, 24, [26] [27] [28] [29] may, therefore, be due not only to higher BP in these patients but also a generalised increased cardiovascular sensibility to BP-induced cardiovascular changes. Therefore, we plan to investigate whether these patients have special genetic polymorphisms within the renin-angiotensin system 33 such as angiotensinconverting enzyme polymorphism (ACE*I/D), angiotensinogen polymorphism (AGT*T/C) and angiotensin II-receptor type 1 polymorphism (AT1R*A/C).
We found like others 9, 10, 34, 35 that elevated urine albumin excretion was associated with known atherogenic factors like smoking, high plasma glucose and old age supporting the idea that elevated urine albumin excretion in hypertension is partly due to early atherosclerosis and perhaps generalised endothelial dysfunction extending to the renal glomeruli facilitating glomerular albumin loss. 36 Elevated urine albumin excretion in the normoalbuminuric range is a cardiovascular risk factor in normotensive individuals 4 suggesting that elevated urine albumin excretion may reflect endothelial dysfunction, which is thought to be one of the first vascular changes in the development of atherosclerosis.
The variability of UACR explained by different atherogenic factors was rather low probably due to the crude manor in which we have measured especially albuminuria. This indicates that we in a clinical setting should not try to predict the presence of end-organ damage in the individual patient only by the presence of atherogenic risk factors. Furthermore, the variability of indices of LV hypertrophy explained by systolic BP and UACR were also low, indicating that even though LV hypertrophy and albuminuria are related it is necessary to measure both in a clinical setting, because it is not possible to predict one with the other.
Finally, it is interesting that logUACR is correlated to BP and LV hypertrophy on ECG in a linear fashion in the entire UACR range, supporting the hypothesis that urine albumin excretion is a continually variable and thereby indicating that high UACR within the normal range as defined in patients with diabetes might have prognostic significance.
Conclusions
The prevalence of LV hypertrophy as well as of microalbuminuria is decreased during 1 year of aggressive BP reduction in high risk hypertensive patients. Increased UACR and LV hypertrophy are related to high systolic BP, but are at the same time interrelated both at baseline and after 1 year of antihypertensive treatment independently of systolic BP. The reduction in UACR is also related to LV hypertrophy regression independently of the reduction in systolic BP. This BP independent relationship between LV hypertrophy and glomerular vascular damage supports either the hypothesis that increased UACR reflects not only glomerular but also systemic vascular changes, or the hypothesis that the cardiovascular system in some patients is more prone to BP-induced changes.
Limitations
The R and ␤ values for the correlations are very small. However, this is probably due the crude manor in which we have measured BP, UACR and LV hypertrophy. Despite this the BP independent association between UACR and indices of LV hypertrophy still persists suggesting that the association is rather robust.
